EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach

Zhiying Gao, Laizhi Luo iD, Yueting Han, Yan Sun, Yonghong Huang, Shixia Li, Xingyun Chen, Huimin Yang, Zhijuan Peng, Xinyi Wang, Wei Zhao, Xi Wu und 5 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Zhiying Gao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Pepsinogen A, Biomarkers, Tumor, Gastrointestinal Stromal Tumors. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Municipal Health Commission, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric GISTs (GG) are significant mesenchymal tumors. No biomarker has been identified for GG detection. We first observed mucosal atrophy surrounding GG tumors, leading to the hypothesis that localized atrophy may alter serum pepsinogen (PG) levels. Therefore, we developed a machine learning (ML) model incorporating serum PG levels and clinical features to predict GG and differentiate it from gastric cancer (GC).

Methods

We retrospectively analyzed GG and GC patients with tested PG levels before medical intervention. Seven ML algorithms were assessed, and feature importance was determined using SHapley Additive exPlanations (SHAP). Gastric atrophy was assessed histologically using the updated Sydney System.

Results

After screening 562 GG and 1090 GC patients, 100 GG and 174 GC samples were included. The multilayer perceptron (MLP) model achieved the highest AUC. The final MLP model, which included 4 features—gender, PGI levels, PGI/PGII ratio, and CEA—predicted GG with an AUC of 0.854. Considering clinical practice and the feature importance identified by the final MLP model, we established a Positive‐Gastric‐GIST‐PG‐CEA criterion (PGI < 70 ng/mL, PGI/PGII ratio ≥ 3.0, and CEA ≤ 5 μg/L) referring to the cutoff values revealed by the ROC curve. The Positive‐Gastric‐GIST‐PG‐CEA displayed exceptional performance in predicting GG (AUC = 0.772, accuracy = 0.748, specificity = 0.787, sensitivity = 0.680), with performance comparable to the final MLP model (ΔAUC = 0.082, p > 0.05). The contributions of PGI levels, PGI/PGII ratio, and CEA in the Positive‐Gastric‐GIST‐PG‐CEA model performance were 0.33, 0.15, and 0.13 based on SHAP analysis. Histopathological evaluation of gastric mucosal atrophy in 50 GG patients revealed peri‐tumoral glandular atrophy in 29 cases (58%).

Conclusions

The Positive‐Gastric‐GIST‐PG‐CEA criterion is valuable for detecting GG and distinguishing it from GC. Integrating our criteria into existing PG tests could help in GG detection without additional economic expense.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPepsinogen ABiomarkers, TumorGastrointestinal Stromal TumorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedMachine LearningAdultAged, 80 and overGastric MucosaROC Curve

Stichwörter der Autor:innen

GISTbiomarkergastric atrophyserum pepsinogenstomach

Substanzen

Pepsinogen ABiomarkers, Tumor

Autor:innen und Institutionen

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Guangzhou Medical University, Guangzhou, China.
  • Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Institute of Pathology, Qiqihar Medical University, Qiqihar, China.
  • Handan Central Hospital, Handan, China.
  • People's Hospital of Xiangxi Autonomous Prefecture, Xiangxi, China.

ORCID-Profile: Laizhi Luo, Yi Ba

Förderung

  • Tianjin Municipal Health Commission
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Gao, Z., Luo, L., Han, Y., Sun, Y., Huang, Y., Li, S., Chen, X., Yang, H., Peng, Z., Wang, X., Zhao, W., Wu, X., Wu, H., Bai, J., Sun, W., Zhou, L., & Ba, Y. (2025). Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach. Cancer Medicine. https://doi.org/10.1002/cam4.71186

Vancouver

Gao Z, Luo L, Han Y, Sun Y, Huang Y, Li S, et al. Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach. Cancer Medicine. 2025. doi:10.1002/cam4.71186

BibTeX
@article{Gao2025,
  author = {Gao, Zhiying and Luo, Laizhi and Han, Yueting and Sun, Yan and Huang, Yonghong and Li, Shixia and Chen, Xingyun and Yang, Huimin and Peng, Zhijuan and Wang, Xinyi and Zhao, Wei and Wu, Xi and Wu, Huan and Bai, Jing and Sun, Wu and Zhou, Likun and Ba, Yi},
  title = {Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71186}
}
Kostenlos starten →